Generating AI analysis...
AI Earnings Analysis
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $3.51M | $37.31M | -90.59% |
Operating Income | $-664.57M | $-466.57M | -42.44% |
Net Income | $-581.6M | $-366.25M | -58.80% |
EPS (Basic) | $-6.47 | $-4.34 | -49.08% |
EPS (Diluted) | $-6.47 | $-4.34 | -49.08% |
R&D Expense | $284.81M | $310.24M | -8.20% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $2.27B | $2.24B | +1.04% |
Current Assets | $1.99B | $1.94B | +2.51% |
Total Liabilities | $343.43M | $309.95M | +10.80% |
Current Liabilities | $149.12M | $87.78M | +69.88% |
Stockholders' Equity | $1.92B | $1.93B | -0.53% |
Cash & Equivalents | $347.56M | $298.26M | +16.53% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $-345.01M | $-142.77M | -141.65% |
Investing Cash Flow | $-31.8M | $-280.48M | +88.66% |
Financing Cash Flow | $426.03M | $331.98M | +28.33% |
D&A | $19.48M | $19.26M | +1.14% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Margin | -18933.6% | -1250.4% | -17683.27% |
Net Margin | -16569.8% | — | — |
ROE | -30.3% | — | — |
ROA | -25.7% | — | — |
Current Ratio | $13.316 | — | — |
Debt to Equity | $0.179 | — | — |
CRSP faced a significant decline in revenue and increased net losses in 2025, driven by operational challenges and cost pressures.
The company experienced a dramatic 90.6% decrease in revenue, indicating significant challenges in its core operations.
Source: Source: 10-K Income Statement, p.1
Operating losses widened by 42.4%, reflecting higher operational inefficiencies and possibly increased costs.
Source: Source: 10-K Income Statement, p.1
Operating cash flow decreased by 141.7%, highlighting liquidity management challenges.
Source: Source: 10-K Cash Flow, p.1
The drastic 90.6% drop in revenue suggests a high dependency on uncertain revenue streams, posing a significant risk to financial stability.
Source: Source: 10-K Income Statement, p.1
Unlock 2 more detailed risk analysis
Other companies in Biotechnology